HIQA on Gene Expression Profiling Tests for Breast Cancer

By Danélia Botes

February 21, 2023

Introduction:

There is an ongoing and unrelenting effort to find better treatments for breast cancer, which is a major health concern worldwide. One promising development in this respect is the use of gene expression profiling (GEP) tests. These tests, performed on tumour samples from early-stage breast cancer patients, can help determine the potential benefits of chemotherapy post-surgery.

Gene Expression Profiling Tests in Breast Cancer:

The Health Information and Quality Authority (HIQA) recently published a rapid health technology assessment (HTA) on GEP tests for breast cancer. This was at the request of the Health Service Executive’s (HSE) National Cancer Control Programme. These tests are particularly useful for patients with the most common form of breast cancer in Ireland. The tests aim to estimate the likelihood of the disease returning and the potential effectiveness of chemotherapy in preventing recurrence.

The Oncotype DX® Test:

Currently, the HSE covers the cost of one GEP test, known as Oncotype DX®. When it comes to patients whose cancer has migrated to their lymph nodes, this test has demonstrated the most compelling proof of its usefulness. On the other hand, the data that supports its use for patients whose cancer has not progressed to their lymph nodes is very restricted.

The Future of GEP Tests:

Despite the promising results of Oncotype DX®, the costs of other GEP tests are not covered. HIQA’s assessment examined the evidence for all four commercially available tests in Ireland. The aim was to provide advice to the HSE on potential alternatives. The decision to cover the cost of other GEP tests will need to consider factors such as patient group applicability, cost, and practicality of use in Ireland.

Conclusion:

Shelley O’Neill, who is the Deputy Director of HTA at HIQA, pointed out that GEP tests have the potential to identify individuals who might not require chemotherapy. This would be beneficial to both the patient and the healthcare system. We need to collect more data on the use of GEP tests in Ireland. This would lead to a more comprehensive evaluation of the potential applications of these tests in the future.

Reference url

Recent Posts

South African National Health Insurance Bill
          

High Court on South African National Health Insurance Bill

📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill

Global Perspective on Orphan Medicines
                

A Global Perspective on Orphan Medicines and Rare Diseases

Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here

            

The Impact of Universal Health Coverage on Poverty Reduction in Low and Middle-Income Countries

📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.